Experimental model of renal tumors in polycystic kidneys: effects of long-term 2-amino-4,5-diphenylthiazole administration in rats treated with N-ethyl-N-hydroxyethylnitrosamine. 1997

K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
Second Department of Pathology, Nara Medical University, Kashihara, Japan.

We previously reported that treatment of Fischer-344 rats with 2-amino-4,5-diphenylthiazole (DPT) results in renal cystic changes. The present study was undertaken to examine the effects of long-term DPT treatment after initiation of kidney carcinogenesis with N-ethyl-N-hydroxyethylnitrosoamine (EHEN) in Wistar rats. One hundred forty-four 6-wk-old male Wistar rats were divided into 6 equal receiving groups: 1000 ppm EHEN or normal tap water for 2 wk followed by 1.06% DPT or basal diet for the subsequent 14 or 30 wk. Controls were maintained without treatment throughout. Subgroups of 6 animals from each group were sacrificed after 8, 16, 24, and 32 wk for histopathological assessment of lesion development in the kidneys and liver. Animals treated with DPT first developed cystic changes of the kidneys (primarily at the corticomedullary border) after 8 wk of treatment, and these changes progressed with time thereafter. In the groups in which DPT treatment was discontinued after 14 wk, cysts then gradually decreased in size. All tumors detected in the kidneys were histopathologically diagnosed as renal cell adenomas. The tumor multiplicity after 32 wk of treatment was significantly higher in Group I, receiving EHEN + DPT for 30 wk (6.33 +/- 4.46), and Group III, receiving EHEN + DPT for 14 wk (3.83 +/- 1.57), than in Group V, EHEN alone (1.00 +/- 0.58) (p < 0.05). Renal cell tumors within cysts were only seen in Groups I and III. The general bromodeoxyuridine labeling indices for the kidneys at week 32 were significantly higher in Group I (55.94 +/- 21.08 cells/mm2) and Group III (53.75 +/- 12.38 cells/mm2) than in Group V (22.38 +/- 6.98 cells/mm2) (p < 0.05). In conclusion, DPT caused cystic changes in rat kidneys, which, however, gradually decreased in size after the treatment was discontinued, suggesting a reversible nature. DPT clearly also promotes renal tumor development after EHEN initiation, and this effect persists, to a certain extent, even after the insult is removed.

UI MeSH Term Description Entries
D007677 Kidney Function Tests Laboratory tests used to evaluate how well the kidneys are working through examination of blood and urine. Function Test, Kidney,Function Tests, Kidney,Kidney Function Test,Test, Kidney Function,Tests, Kidney Function
D007680 Kidney Neoplasms Tumors or cancers of the KIDNEY. Cancer of Kidney,Kidney Cancer,Renal Cancer,Cancer of the Kidney,Neoplasms, Kidney,Renal Neoplasms,Cancer, Kidney,Cancer, Renal,Cancers, Kidney,Cancers, Renal,Kidney Cancers,Kidney Neoplasm,Neoplasm, Kidney,Neoplasm, Renal,Neoplasms, Renal,Renal Cancers,Renal Neoplasm
D007690 Polycystic Kidney Diseases Hereditary diseases that are characterized by the progressive expansion of a large number of tightly packed CYSTS within the KIDNEYS. They include diseases with autosomal dominant and autosomal recessive inheritance. Kidney, Polycystic,Polycystic Kidney,Polycystic Kidney Disease,Polycystic Kidneys,Polycystic Renal Disease,Disease, Polycystic Kidney,Disease, Polycystic Renal,Diseases, Polycystic Kidney,Diseases, Polycystic Renal,Kidney Disease, Polycystic,Kidney Diseases, Polycystic,Kidneys, Polycystic,Polycystic Renal Diseases,Renal Disease, Polycystic,Renal Diseases, Polycystic
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D001973 Bromodeoxyuridine A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors. BUdR,BrdU,Bromouracil Deoxyriboside,Broxuridine,5-Bromo-2'-deoxyuridine,5-Bromodeoxyuridine,NSC-38297,5 Bromo 2' deoxyuridine,5 Bromodeoxyuridine,Deoxyriboside, Bromouracil
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D004052 Diethylnitrosamine A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. Nitrosodiethylamine,N-Nitrosodiethylamine,N Nitrosodiethylamine

Related Publications

K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
August 2000, Toxicology and applied pharmacology,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
December 1979, Gan,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
February 1984, Journal of the National Cancer Institute,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
February 1999, Cancer letters,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
October 1982, Journal of the National Cancer Institute,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
November 1985, Kidney international,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
April 1983, Journal of the National Cancer Institute,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
July 1992, Japanese journal of cancer research : Gann,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
December 1991, Japanese journal of cancer research : Gann,
K Tsumatani, and Y Nakagawa, and Y Kitahori, and N Konishi, and H Uemura, and S Ozono, and Y Hirao, and E Okajima, and K Hirao, and Y Hiasa
July 1984, Journal of the National Cancer Institute,
Copied contents to your clipboard!